Agios Pharmaceuticals (AGIO) Accounts Payables (2012 - 2026)

Agios Pharmaceuticals has reported Accounts Payables for 15 years, with the latest figure at $13.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables changed 0.15% year-over-year to $13.7 million; the trailing twelve-month figure through Mar 2026 stood at $13.7 million (changed 0.15% YoY), and the FY2025 full-year result was $18.4 million, up 10.29% from the prior year.
• Accounts Payables for Q1 2026 stood at $13.7 million, down from $18.4 million in the prior quarter.
• The five-year high for Accounts Payables was $19.6 million in Q3 2025, with the low at $7.8 million in Q2 2022.
• Historically, Accounts Payables has averaged $13.5 million across 5 years, with a median of $13.3 million in 2023.
• Annual changes were most pronounced in 2022 — Accounts Payables plunged 77.45% — and 2025, when it jumped 74.71%.
• Agios Pharmaceuticals' Accounts Payables stood at $18.6 million in 2022, then sank by 47.46% to $9.8 million in 2023, then surged by 70.17% to $16.6 million in 2024, then advanced by 10.29% to $18.4 million in 2025, then slipped by 25.1% to $13.7 million in 2026.
• The last three Accounts Payables figures came in at $13.7 million (Q1 2026), $18.4 million (Q4 2025), and $19.6 million (Q3 2025), per Business Quant data.